News Releases

Conference Call and Live Audio Webcast Scheduled for Thursday, November 9, 2023, at 10:00 a.m. ET Corporate Highlights Third quarter of 2023 GAAP net income was $4.5 million or $0.36 per diluted...

Conference Call and Live Audio Webcast Scheduled for Thursday, November 9, 2023, at 10:00 a.m. ET DALLAS, Nov. 6, 2023 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the...

SWK Holdings Corporation (NASDAQ: SWKH) ("SWK" or the "Company") today announced that B. Riley Securities has exercised its option to purchase $2,968,750 in additional unsecured Senior notes (the...

SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a...

SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life-science-focused, specialty finance company catering to small- and mid-sized commercial-stage companies, today announced an...

SWK Holdings Corporation (NASDAQ: SWKH) ("SWK" or the "Company") today announced that it has completed its previously announced registered underwritten public offering (the "Offering") of $30...

SWK Holdings Corporation (NASDAQ: SWKH) ("SWK" or the "Company") today announced that it has priced its previously announced registered underwritten public offering (the "Offering") of $30 million...

SWK Holdings Corporation (NASDAQ: SWKH) ("SWK" or the "Company") today announced that it plans to offer $30 million in aggregate principal amount of senior unsecured notes due 2028 (the "Notes")...

Conference Call and Live Audio Webcast Scheduled for Wednesday, August 9, 2023, at 5:00 p.m. ET Corporate Highlights Second quarter 2023 GAAP net income was $3.9 million or $0.31 per diluted...

Conference Call and Live Audio Webcast Scheduled for Wednesday, August 9, 2023, at 5:00 p.m. ET DALLAS, Aug. 8, 2023 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the...

SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a...

SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, announced the...

Conference Call and Live Audio Webcast Scheduled for Thursday, May 11, 2023, at 10:00 a.m. ET Corporate Highlights First quarter 2023 GAAP net income was $4.6 million or $0.36 per diluted share,...

Conference Call and Live Audio Webcast Scheduled for Today, April 3, 2023, at 10:00 a.m. ET Corporate Highlights Jody Staggs named President and Chief Executive Officer Appointed Laurie Dotter as...

Conference Call and Live Audio Webcast Scheduled for Monday, April 3, 2023, at 10:00 a.m. ET DALLAS, March 31, 2023 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the...

SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that...

SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an...

Mr. Staggs elevated from "interim" to "permanent" CEO as SWK advances multiple initiatives in 2023 Ms. Dotter joined SWK's Board of Directors in February 2022 DALLAS, Jan. 3, 2023 /PRNewswire/ --...

SW K Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, announced the...

Conference Call and Live Audio Webcast Scheduled for Thursday, November 10, 2022, at 10:00 a.m. ET Corporate Highlights Successful leadership transition with Jody Staggs named President and...

Conference Call and Live Audio Webcast Scheduled for Thursday, November 10, 2022, at 10:00 a.m. ET DALLAS, Nov. 8, 2022 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ: SWKH) ("SWK" or the...

Oral Presentation Delivered at the American Society for Reproductive Medicine Scientific (ASRM) 2022 Congress & Expo BOONTON, N.J., Oct. 26, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a...

SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an...

SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned...

Yvette Heinrichson promoted to Chief Financial Officer John David Tamas promoted to Director of Underwriting DALLAS, Oct. 3, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or...

Physicochemical properties of peptides can provide key insights to potential success of oral delivery BOONTON, N.J., Sept. 12, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company...

SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that...

Jody Staggs appointed as President and Interim CEO CEO Winston Black will assist in an interim consulting role after successfully establishing SWK Holdings as a leading life science focused...

Conference Call and Live Audio Webcast Scheduled for Thursday, August 11, 2022, at 10:00 a.m. ET Corporate Highlights Celebrated 10th anniversary as a life science focused specialty finance...

Conference Call and Live Audio Webcast Scheduled for Thursday, August 11, 2022, at 10:00 a.m. ET DALLAS, Aug. 9, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the...

Article describes Enteris' strengths and scalability in working with highly potent active pharmaceutical ingredients BOONTON, N.J., August 3, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

Since 2012, SWK Holdings has completed financings with 46 life sciences companies, deploying $650 million of capital Second Quarter 2022 Financial Results to be Announced in August DALLAS, July...

SWK Holdings Corporation (Nasdaq: SWKH), a life science-focused specialty finance company catering to small-and mid-sized commercial-stage companies, announced today its addition to the Russell...

Data suggest that oral formulations of leuprolide developed utilizing Enteris' Peptelligence® platform successfully deliver meaningful circulating drug concentrations and achieve hormonal...

Facilities and processes key to protecting workers and the environment, the paper in Drug Development & Delivery says BOONTON, N.J., June 7, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a...

Enteris BioPharma, Inc. gave plush animals a dose of personality as they created a dozen stuffed teddy bears for Ronald McDonald House Charities to help comfort sick children as they undergo...

SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, announced today that...

In the news release, SWK Holdings Corporation Announces Financial Results for First Quarter 2022, issued 11-May-2022 by SWK Holdings Corporation over PR Newswire, we are advised by the company...

Conference Call and Live Audio Webcast Scheduled for Wednesday, May 11, 2022, at 10:00 a.m. ET DALLAS, May 10, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

Article describes unique features of Enteris' Peptelligence® and ProPerma® peptide and small molecule oral delivery technology BOONTON, N.J., April 4, 2022 /PRNewswire/ -- Enteris BioPharma,...

Conference Call and Live Audio Webcast Scheduled for Monday, March 28, 2022, at 10:00 a.m. ET Corporate Highlights Reconstituted Board and appointed Wendy DiCicco, Robert K. Hatcher, and Laurie Dotter

Advanced Oxygen Therapy Inc. (AOTI), the global leader in noninvasive topical oxygen wound healing solutions, announced today they have closed a significant round of growth funding from the...

SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that...

NEWTON, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced the reconstitution of the...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") today announced that the special committee of the Company's board of directors (the "Special Committee") has concluded its...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

REDWOOD CITY, CA / ACCESSWIRE / December 27, 2021 /Biotricity Inc. (NASDAQ:BTCY) a modern medical technology company delivering innovative, remote biometric monitoring solutions, today announced...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned...

SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") confirmed that on November 23, 2021, it received a non-binding proposal from funds managed by Carlson Capital, L.P. ("Carlson") to...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

Corporate Updates Conclusion of strategic review process with SWK to focus on specialty finance receivables business SWK evaluating ongoing dividend and additional leverage Third Quarter 2021...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided an...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

Corporate Updates The Specialty Finance Receivables and Pharmaceutical Development segments each reported strong quarters Closed a $5.0 million synthetic royalty transaction in April 2021 and a...

SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an...

SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

Corporate Updates YTD SWK has closed two financings totaling up to $14.0 million Enteris BioPharma subsidiary announced completion of manufacturing facility expansion and launch of CDMO business...

The Board of Directors (the "Board") of SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") and its controlling stockholder, funds affiliated with Carlson Capital, L.P. ("Carlson"),...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") confirmed that on April 5, 2021, a Special Committee (the "Special Committee") of the Company's Board of Directors received a...

Corporate Highlights Closed four transactions in 2020 deploying $34.8 million; additional $8.1 million deployed to existing borrowers Income producing assets as of December 31, 2020 reached an...

Sincerus Pharmaceuticals, the parent company of Prescriber's Choice and Sincerus Florida, today announced the completion of a major new round of growth financing with SWK Holdings Corporation (Nasdaq:

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that Winston Black, Chairman...

SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided an update on the progress and...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...

Rajiv Khosla, Ph.D., named Chief Executive Officer Gary A. Shangold, M.D., appointed Chief Medical Officer Received two milestone payments totaling $5 million from Cara Therapeutics per licensing...

Flowonix Medical, Inc., a medical device company focused on providing advanced, implantable drug delivery solutions and SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty...

SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned...

WATERTOWN, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative therapeutics to...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...

Corporate Highlights Enteris BioPharma, Inc., ("Enteris") a wholly-owned subsidiary of SWK Holdings, recognized $2.5 million in milestone revenue under the license agreement with Cara...

SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, today announced that its chairman and chief executive officer, Winston Black, will participate in...

SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on the progress and...

UK-based ostomy specialist Trio Healthcare has secured a multi-million-pound financing from US specialised finance company, SWK Holdings Corporation, as the company targets significant domestic...

SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned...

SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, today announced that its chairman and chief executive officer, Winston Black, will present at two...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...

SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, today announced that its chairman and chief executive officer, Winston Black, will participate in the...

PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing and closing of a definitive agreement for the sale of three royalty interests for Kybella®, Zalviso®, and...

Corporate Highlights Rajiv Khosla, Ph.D. appointed as Chief Executive Officer of Enteris BioPharma Repurchased $1.0 million of common stock during the three-month span ended June 30, 2020 SWK...

SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, announced that the Company will host a conference call and live audio webcast on Monday, August 17, 2020,...